Recent literature emphasizes the necessity to optimize the pharmacological treatment in type-2 diabetes to effectively mitigate the risk of major and mild CI, particularly among individuals at an elevated risk of these clinical conditions
Tirzepatide and sermorelin together represent a combination therapy approach that some patients and clinicians consider for metabolic management, though this pairing lacks formal clinical study
European journal of nutrition , 54 (2), 251-263
R01CA245314, R01CA211184, R01CA034992, R01CA257523, R01DK140310, P30CA014051 and R01DK126545), a Pew-Stewart Trust scholar award, the Kathy and Curt Marble cancer research award, a Koch InstituteDana-Farber/Harvard Cancer Center Bridge project grant and AFAR
As weight decreases, existing antihypertensive doses may become relatively excessive, causing low blood pressure or dizziness